All In Biotech

Drug Trial Radar · NCT07079228

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

A Phase 3, Multi-Center, Double-blind, Randomized Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

602

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Dec 2028

Study completion Sep 2030

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.

Conditions

  • Pancreatic Cancer

Interventions

  • QLS31905Drug

    QLS31905 will be administered as an IV infusion.

  • Nab-paclitaxel.Drug

    Nab-paclitaxel will be administered as an IV infusion.

  • GemcitabineDrug

    Gemcitabine will be administered as an IV infusion.

  • Placebo for QLS31905Drug

    Placebo will be administered as an IV infusion.

  • Nab-paclitaxel.Drug

    Nab-paclitaxel will be administered as an IV infusion

  • GemcitabineDrug

    Gemcitabine will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Suryival(OS)Time frame: Up to 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.